An Examination of the effect of cancer education by using word-of-mouth: cervical cancer prevention program in Japan.-A study on the effect verification of the positive recommendation leaflet of cervical cancer prevention vaccine applying nudge theory-. - Regional Randomized Trial of Cervical Cancer Leaflet.

开始日期2023-06-30

申办/合作机构-

NCT03550755 / Unknown status临床2期

Open Label Single Arm Phase II Immunotherapy Trial in Patients With Cervical Cancer

The goal of this trial is to evaluate the efficacy of immunotherapy for cervical cancer based on a fundamentally new approach. We will test new tableted preparation, V3-Cervix, obtained from hydrolyzed, inactivated blood and tumors of patients with cervical cancer. When administered orally, it should cause a specific anti-tumor immune response and an anti-inflammatory effect. Trial is planned to last 3 months, recruit 20 volunteers, administer daily pill of vaccine and evaluate effect on tumor size and tumor markers.

开始日期2018-07-01

申办/合作机构

Immunitor, Inc.

100 项与 Cervical cancer vaccine(Immunitor, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Cervical cancer vaccine(Immunitor, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Cervical cancer vaccine(Immunitor, Inc.) 相关的专利（医药）

登录后查看更多信息

126

项与 Cervical cancer vaccine(Immunitor, Inc.) 相关的文献（医药）

2024-08-31·Osong public health and research perspectives

Immunoinformatics approach for design novel multi-epitope prophylactic and therapeutic vaccine based on capsid proteins L1 and L2 and oncoproteins E6 and E7 of human papillomavirus 16 and human papillomavirus 18 against cervical cancer

Article

作者: Mahyarudin, Mahyarudin ; Ryan, Nicholas ; Liana, Delima Fajar ; Mardhia, Mardhia ; Pratiwi, Sari Eka ; Ysrafil, Ysrafil

Objectives: This study aimed to identify the optimal protein construction for designing a multi-epitope vaccine with both prophylactic and therapeutic effects against cervical cancer, utilizing an immunoinformatics approach. The construction process involved using capsid epitopes L1 and L2, as well as oncoproteins E5, E6, and E7 from human papillomavirus (HPV) types 16 and 18.Methods: An experimental in silico analysis with an immunoinformatics approach was used to develop 2 multi-epitope vaccine constructs (A and B). Further analysis was then conducted to compare the constructs and select the one with the highest potential against cervical cancer.Results: This study produced 2 antigenic, non-allergenic, and nontoxic multi-epitope vaccine constructs (A and B), which exhibited the ideal physicochemical properties for a vaccine. Further analysis revealed that construct B effectively induced both cellular and humoral immune responses.Conclusion: The multi-epitope vaccine construct B for HPV 16 and 18, designed for both prophylactic and therapeutic purposes, met the development criteria for a cervical cancer vaccine. However, these findings need to be validated through in vitro and in vivo experiments.

2023-01-01·South Asian journal of cancer

Audio-Visual Training Improves Awareness and Willingness of Cervical Cancer Screening among Healthy Indian Women: Findings from a Survey

Article

作者: Ganeshkumar, Priya

Objectives We evaluated the impact of a standardized, simple audio-visual (AV) training video developed in regional languages on cervical cancer awareness among apparently healthy women and their willingness to undergo regular cervical cancer screening. Materials and Methods This cross-sectional noninterventional multicentric survey was conducted in 69 centers across 14 states in India and one center in UAE among women aged between 18 and 88 years attending clinics for a variety of indications. Using a short questionnaire, cervical cancer awareness and willingness to undergo cervical cancer screening were assessed before and after the AV training. Statistical Analysis In addition to descriptive analysis, improvement in awareness after the AV training was assessed using McNemar's test, and comparison of responses between subgroups was performed using Pearson chi-squared test. Results The survey was completed by 3,188 apparently healthy women (mean age: 36.8 ± 11.3 years). Before AV training, correct answers were given to only 4/6 questions by majority of the participants; most participants were unaware about the main cause of cervical cancer (1,637/3,188, 51.4%), availability of cervical cancer screening tests (1,601/3,188, 50.2%), and cervical cancer vaccines (1,742/3,188, 54.6%). Only 576 women (18.1%) had undergone cervical cancer screening in the past. After the AV training, the proportion of women correctly responding to all six questions improved significantly (p < 0.05), and 84.4% (2691/3188) women showed willingness to undergo periodic cervical cancer screening. Compared to unmarried and professional women, although married women and home-makers had lower awareness scores, the latter subgroups had more often undergone previous cervical cancer screening. Conclusion It is possible to improve cervical cancer awareness among healthy women, and to enhance their willingness to undergo regular cervical cancer screening tests using a simple, six minute-long, standardized AV training material.

2023-01-01·Cancer treatment and research communications

Human papilloma virus vaccines: A comprehensive narrative review

Review

作者: Singh, Amit Kumar ; Aggarwal, Sumit ; Agarwal, Pragati

Cervical cancer is one of the most common cancers in women aged 15-44 years in the world, with more than three-quarters of cases diagnosed at a locally advanced clinical stage with minor prospects of survival. Although only a small percentage of women with Human Papilloma Virus (HPV) develop cervical cancer and most of the HPV infections are cleared subsequently at primary stage itself, but seroconversion not always guarantees that the individual is immune to HPV. The advent of the cervical carcinoma vaccine has raised the expectations that eradication of cervical carcinoma might be possible in the near future as it exhibited remarkably high efficacy against the vaccine-specific types in naive women with no serious vaccine-related adverse events. Few prophylactic HPV vaccines are currently licensed in over 100 countries. It has also been suggested that vaccinating both men and women is more beneficial than vaccinating only females. Vaccination is a cost-effective strategy to reduce the incidence of cervical cancer and mortality compared to no vaccination based on the cost of cancer treatment. Well-coordinated vaccination strategy with focus on adolescent girls and if possible, boys can lead to dramatic impact on disease reduction around the world.

项与 Cervical cancer vaccine(Immunitor, Inc.) 相关的新闻（医药）

2023-11-20

·BioSpace

5 Cancer Vaccines to Watch in 2024

Pictured: Vaccine bottles/iStock, May Lim Several cancer vaccine candidates are flying through clinical trials with promising results. Unlike traditional vaccines that aim to prevent a disease from occurring, therapeutic cancer vaccines train the patient’s immune system, enabling T cells to patrol the body for cancer cells and destroy them. Progress in personalized medicine has made it easier and much more affordable to sequence patient genomes, pull out unique cancer signatures and make vaccines encoding these neoantigens. BioSpace compiled a list of five cancer vaccines in mid- to late-stage development and sought insights from two experienced researchers on their respective merits. Moderna and Merck’s Melanoma Vaccine Generating possibly the most attention is Moderna and Merck’s mRNA-based vaccine for metastatic melanoma. In July, the partners announced a Phase III trial for the vaccine, dubbed mRNA-4157, which will be delivered alongside the immune checkpoint inhibitor Keytruda (pembrolizumab). This announcement was made following the release of positive Phase IIb results in April that showed patients treated with mRNA-4157 plus Keytruda had a 44% lower risk of cancer recurrence or death than patients treated with Keytruda alone. mRNA-4157 is made up of a single synthetic mRNA that can encode up to 34 neoantigens derived from patients’ distinct genetic cancer signatures. When translated, the neoantigens trigger the activation and multiplication of T cells, which surveil the body for cancer cells expressing them. The encouraging Phase IIb results also prompted the FDA to grant the vaccine Breakthrough Therapy Designation. Curiously, patients with both high and low tumor mutational burdens (TMBs) showed similar responses to the mRNA therapy. This counters historical correlations of high TMB and the success of immunotherapy, particularly for melanoma. Ryan Sullivan, a medical oncologist at the Dana-Farber Harvard Cancer Center who has served as the principal investigator on several clinical trials for cancer therapeutics, including one looking at the effectiveness of mRNA-4157 across TMB levels, posed the question, “Is there something about the vaccine that helps to overcome the lack of a TMB?” Sullivan said Merck and Moderna have expressed interest in investigating the link between TMB and therapeutic efficacy in Phase III. The trial, which will recruit 1089 participants, is expected to be completed in 2029. BioNTech’s Pancreatic Cancer Vaccine BioNTech announced in October that the first patient in a Phase II trial of autogene cevumeran, an mRNA vaccine against pancreatic ductal adrenal cancer (PDAC), had been treated. The vaccine, which consists of an mRNA encoding for up to 20 neoantigens tailor-made for different patients, is delivered alongside the immune checkpoint inhibitor atezolizumab. The open-label, randomized trial has two arms. In the first, patients are treated with a combination of the vaccine, atezolizumab and standard chemotherapy. These patients will be compared to a second arm of patients who receive only standard chemotherapy. The vaccine, jointly developed by BioNTech and Genentech, was previously tested against a host of solid tumors in a Phase I trial where it triggered a large cohort of neoantigen-specific T cells in PDAC patients, many of whom went for long periods without cancer recurrence. This is particularly important for PDAC, which has a high relapse rate and is notoriously difficult to treat. The Phase II trial will recruit 206 patients and is expected to be completed in 2029. “I think we’re all interested in some of the new epitope trials with pancreatic cancer just because it’s so universally deadly and difficult to treat,” said Zachary Hartman, an associate professor at Duke University School of Medicine who studies how to harness immune responses to treat cancer. In addition to PDAC, autogene cevumaren is being tested in Phase II trials for colorectal cancer and melanoma. Transgene’s Viral Vector-Based Vaccine French biotech Transgene announced promising results for its viral vector-based vaccine, TG4050, developed in partnership with NEC Corporation. The vaccine, which is currently in Phase I trials for ovarian cancer and HPV-negative head and neck cancer, has shown robust immune responses in patients. The ability to generate a strong immune response, especially in cancer patients who may already have weakened immune systems, is the first indicator that a cancer vaccine can be effective. Indeed, TG4050 has evoked T cell activity even in patients who are over 65 or have low circulating lymphocyte counts at baseline, Transgene CSO Eric Quéméneur told BioSpace in an email. Trial participants treated with the vaccine remained disease-free as of June 2023, and the company expects both studies to be completed in 2024. The vaccines, developed using Transgene’s trademark myvac platform, carry neoantigens selected by NEC’s AI-based system. The neoantigens are customized for each patient and reflect their unique cancer mutations, opening the door to treating many more types of cancer. “I think you can make an argument that virtually any tumor type might benefit from this type of vaccination,” Sullivan said. OSE’s Advanced NSCLC Vaccine In September, OSE Immunotherapeutics published positive results from a Phase III trial of its cancer vaccine for advanced non-small cell lung cancer (NSCLC). Branded Tedopi and approved for compassionate use in France, Italy and Spain, the vaccine is a mix of antigenic peptides meant to activate anti-tumor T cells. The antigens were selected because they are commonly expressed in patients with NSCLC and the HLA-A2 phenotype. Importantly, the 219 trial participants had already been treated with immune checkpoint inhibitors and chemotherapy but had either developed resistance to the former or had not responded to the latter. Participants treated with Tedopi had markedly better survival and quality of life than those who received standard chemotherapy. These results carry promise for patients who have exhausted conventional modes of treatment and do not have many remaining options. Tedopi is also being tested in Phase II trials for the treatment of PDAC and recurrent ovarian cancer. Nykode’s Cervical Cancer Candidate Norway–based Nykode Therapeutics in April announced positive results for the Phase IIa trial of its cervical cancer vaccine. The vaccine, VB10.16, was delivered to 52 trial participants in combination with atezolizumab. Patients who received the vaccine were tracked for one year and showed a median overall survival of 16.9 months. A second, larger trial of VB10.16 in cervical cancer is set to begin later this year. Nykode’s vaccine design is different from that of others on this list. VB10.16 is a plasmid DNA-based vaccine encoding a three-part Vaccibody. Of the three units, one is a collection of up to 20 neoantigens and the other is a targeting unit that attracts antigen-presenting cells (APC). Depending on the type of APC attracted, the vaccine can activate either T cells, which kill cells carrying the neoantigen, or B cells, which make antibodies against the neoantigen-bearing cells. Hartman stressed the importance of prioritizing both antibody and T cell responses to cancers. “Antibodies are kind of like the right arm of the immune system, and T cells might be the left arm, so to be an effective fighter you need both.” He added that most cancer vaccine studies tend to ignore antibody responses, which is “something that we would neglect at our own peril.” Both Hartman and Sullivan expressed optimism about current progress with cancer vaccines. “If these early trials are showing benefit, I think the sky’s the limit in terms of where we’re going with tumor vaccination,” Sullivan said. Sruthi S. Balakrishnan is a freelance academic editor, science writer and fact-checker based in Santa Barbara, California. She can be reached at sruthisb@sciscriber.com.

临床结果临床2期疫苗临床3期临床1期

2023-02-24

·Pharmaceutical Technology

The one-shot cervical cancer vaccine paradigm

Prophylactic HPV vaccination and anal cancer in Thailand. Image Credit: Shutterstock/CNK02 On December 20, 2022, the World Health Organization (WHO) updated its recommendations for cervical cancer vaccines in a bid to boost vaccination coverage. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country * United Kingdom United States Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D"ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People"s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People"s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Submit By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report. The WHO now says that a one-dose schedule for girls ages 9–14 years adequately protects against human papillomavirus (HPV), and more specifically, the HPV 16 and HPV 18 strains. The insights and amendments came following findings from a meeting held by WHO’s independent expert advisory group in April 2022. Several cervical cancer vaccines are currently approved, including Merck’s nonavalent vaccine Gardasil 9 and GSK’s bivalent vaccine Cervarix. In September 2022, the Drugs Controller General of India (DCGI) approved its first indigenously produced quadrivalent cervical cancer vaccine, developed by the Serum Institute of India. “The HPV vaccine works almost perfectly to prevent HPV infection, the necessary cause of cervical cancer and other HPV-related cancers,” says Dr. Ruanne Barnabas, professor of Medicine at Harvard Medical School and researcher on the study that informed the WHO’s updated recommendations. “The vaccine is also safe, with millions of doses administered globally,” she continues. Potential changes with a single-dose schedule “Before the new WHO guidelines, either two or three doses of the current vaccines were administered,”says Barnabas. People up to age 14 years were given two doses of the vaccine, and those ages 15 years and older received three doses. All prophylactic HPV vaccine products are delivered intramuscularly in the arm, specifically the deltoid region, at a standard dose of 0.5ml. After studying the single-dose bivalent and nonavalent HPV vaccines, researchers found that they were both highly effective in avoiding incident persistent oncogenic HPV infection, similar to multidose programs. Current HPV vaccination coverage levels sit at 15%, Barnabas shares, compared to the WHO’s goal of giving 90% of eligible adolescents, or those ages 9–14 years, the HPV vaccine. “ The cost of HPV vaccines is also high compared to other vaccines ,” Barnabas adds. The ability to use one dose would decrease the program’s overall cost, making the vaccine more accessible to more people. This would be “ the key improvement” of a single-dose schedule, says Barnabas. For low-resource countries that have not yet introduced the vaccine, particularly middle-income countries (MICs) that are eligible for supplies from the nonprofit GAVI, the singular dose will lower the budget requirement for HPV, says Paul Bloem, Technical Officer, Lead HPV vaccine strategy of the Immunization, Vaccines and Biologicals (IVB) Department at the WHO. A new vaccine like HPV, which is relatively more expensive than a traditional one like the diphtheria, pertussis, and tetanus (DTP) vaccine, can significantly increase the overall budget of a national vaccination program. “The single dose will lower that barrier,” Bloem confirms. A single-dose schedule offers opportunities for ease of delivery and the possibility to add HPV to other one-off campaigns to boost coverage. It may also result in fewer administrative requirements compared to full-dose schedule tracking. Programs to catch up with older age groups, such as those up to age 18 years, could also benefit from requiring one dose rather than three. New schedule rollout As the WHO issues new guidance, each country is expected to take steps to increase the impact of its vaccination program. Democratizing access to the vaccine appears to be a key goal of the single-dose vaccine, particularly as its cost is a barrier. The study that led to the WHO’s recommendations found that 80% of new cervical cancer cases are in women living in low-income and MIC, with the highest mortality found in sub-Saharan Africa. One 2022 study found that cervical cancer accounts for the second-highest cancer burden among women of all ages in Nigeria. Overcoming health system limitations related to health worker availability, infrastructure, and logistics is crucial, the study revealed, as is social awareness and mobilization. However, a 2021 research study found that despite the implementation of vaccination programs, there is low awareness of HPV infection and its vaccine, particularly in developing countries. The WHO’s 2020 global strategy sets out its vision of cervical cancer being eliminated as a public health problem by 2030 and outlines a pathway with strategic actions to achieve its goal. While Bloem said high-income countries (HIC) like the UK are moving to a one-dose schedule , he expected others to shift in the next few years while some, particularly Upper-MIC and HIC, may wait. Current vaccination rates are variable According to the data published in July 2022, the global vaccine coverage by full dose is 12%, and by single dose is 15%. The North American region has the highest vaccine coverage (38%), although coverage was at more than 50% before the Covid-19 pandemic, followed by Europe (27%) and the African region (21%). Asia has less than 10% vaccine coverage because two big countries, India and China, are yet to introduce it [on a national level], Bloem says. Australia is on track to eliminate cervical cancer as a public health problem. Various barriers have led to vaccination rates in most parts of the world remaining relatively low. “The main obstacles have been the high vaccine cost, low supply, and insufficient advocacy,” says Barnabas. Many countries struggle with HPV vaccination communication despite their income status. “Even though the WHO has repeatedly evaluated and announced that the HPV vaccine is an extremely safe vaccine, vaccine hesitancy still remains an issue,” says Bloem. Additionally, the sexual transmission of HPV has been an “unnecessary focus of attention”, Barnabas shares, stating that the lifetime risk of HPV is almost 100% for sexually active persons, and thus, HPV is part of everyday life. “Given that almost 100% of cervical cancers are caused by HPV and that the vaccine is nearly perfect in preventing almost 100% of infections, effective programs would prevent disease and death among women in their mid-adult years and contribute to healthier families and communities,” Barnabas shares. Another challenge is a programmatic one, Bloem highlights, since the HPV vaccine is somewhat unique compared with childhood vaccines in terms of target age and sex. The primary target cohort is girls ages 9–14 years, which stands alone from other childhood vaccine services. Since these adolescents are less likely to come to the hospital than babies and children, the focus needs to be on actively reaching out to those populations by using available platforms, such as school-based vaccinations. However, in some resource-limited countries, it is hard to reach those cohorts due to low school attendance rates, geographical challenges, and religious barriers. Free Report How is the Biopharmaceutical industry evolving? 2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to: Benchmark the impact of major themes on the Biopharmaceutical industry. Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents. Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success. By GlobalData Submit Country * United Kingdom United States Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D"ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People"s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People"s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Submit By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services. Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. Please check your email to download the Report.

疫苗上市批准临床结果

2008-12-04

·Pharma Times

GSK cuts jobs in Durham due to decline in demand for Zofran

GlaxoSmithKline is to cut 200 jobs at its Barnard Castle, County Durham plant over the next 12 to 18 months as a result of a decline in demand for the nausea drug Zofran, which is manufactured at the site. Roger Connor, site director at Barnard Castle, said that the firm “very much regrets the need for these proposed job losses but they are essential to remain competitive within the global pharmaceutical market”. He added that “it is a difficult proposal for the company to make” but emphasised that “it is not a reflection on the quality of our staff or on our commitment to the Barnard Castle site”. Around 960 staff currently work at the facility, which produces over 40 drugs. However the site’s principal product is Zofran (ondansetron) for chemotherapy-induced nausea, which is already coming under pressure from generic competition. Third-quarter sales of the drug fell 9% to £33 million. News of the Durham cuts comes a month after GSK announced it was closing its manufacturing site in Dartford in 2013, which will result in the loss of 620 jobs. The closure is due to reduced demand for Lamictal (lamotrigine) for epilepsy and bipolar disorder and Valtrex (valaciclovir) for herpes. Cervarix price cut in South Africa Meantime, GSK has slashed the price of its cervical cancer vaccine Cervarix in South Africa. David Pritchard, general manager of the firm’s operations in the country, announced a 36% reduction in the price to 450 rand per dose, about £30. Mr Pritchard noted that in a developing country such as South Africa, “affordability is an important issue and with this reduction in cost we will be bringing the cervical cancer vaccine within direct reach of many more South African women". He added that GSK hopes to work in close partnership with other stakeholders including government “to further increase the availability of cervical cancer vaccines through better infrastructure, wider distribution, better disease awareness, education and affordability”.

疫苗合作

100 项与 Cervical cancer vaccine(Immunitor, Inc.) 相关的药物交易

登录后查看更多信息